UA75022C2 - Method for treating late phase allergic reactions or inflammatory diseases and pharmaceutical composition - Google Patents
Method for treating late phase allergic reactions or inflammatory diseases and pharmaceutical composition Download PDFInfo
- Publication number
- UA75022C2 UA75022C2 UA2000020607A UA2000020607A UA75022C2 UA 75022 C2 UA75022 C2 UA 75022C2 UA 2000020607 A UA2000020607 A UA 2000020607A UA 2000020607 A UA2000020607 A UA 2000020607A UA 75022 C2 UA75022 C2 UA 75022C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antigen
- differs
- fact
- reactions
- late
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 208000027866 inflammatory disease Diseases 0.000 title description 5
- 208000006673 asthma Diseases 0.000 claims abstract description 46
- 230000004054 inflammatory process Effects 0.000 claims abstract description 18
- 206010061218 Inflammation Diseases 0.000 claims abstract description 14
- 150000004676 glycans Chemical class 0.000 claims abstract description 13
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 11
- 239000005017 polysaccharide Substances 0.000 claims abstract description 11
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 10
- 230000037396 body weight Effects 0.000 claims abstract description 10
- 229940127215 low-molecular weight heparin Drugs 0.000 claims abstract description 8
- 239000000427 antigen Substances 0.000 claims description 161
- 102000036639 antigens Human genes 0.000 claims description 161
- 108091007433 antigens Proteins 0.000 claims description 161
- 238000006243 chemical reaction Methods 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 50
- 229960002897 heparin Drugs 0.000 claims description 46
- 229920000669 heparin Polymers 0.000 claims description 46
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000000443 aerosol Substances 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 210000002345 respiratory system Anatomy 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 150000004044 tetrasaccharides Chemical class 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 230000000172 allergic effect Effects 0.000 claims description 8
- 238000005259 measurement Methods 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 230000035945 sensitivity Effects 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 230000003385 bacteriostatic effect Effects 0.000 claims description 3
- 239000002565 heparin fraction Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000003380 propellant Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 2
- 229920002971 Heparan sulfate Polymers 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 2
- 229940051593 dermatan sulfate Drugs 0.000 claims description 2
- 239000000644 isotonic solution Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229940043138 pentosan polysulfate Drugs 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 206010003559 Asthma late onset Diseases 0.000 claims 1
- 206010040914 Skin reaction Diseases 0.000 claims 1
- 231100000430 skin reaction Toxicity 0.000 claims 1
- 230000035483 skin reaction Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract description 2
- 206010012434 Dermatitis allergic Diseases 0.000 abstract description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 2
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract description 2
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract description 2
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 abstract 1
- 230000010085 airway hyperresponsiveness Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 86
- 239000003814 drug Substances 0.000 description 57
- 229940079593 drug Drugs 0.000 description 54
- 241001494479 Pecora Species 0.000 description 44
- 230000000694 effects Effects 0.000 description 38
- 206010006487 Bronchostenosis Diseases 0.000 description 34
- 239000008279 sol Substances 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 31
- 238000002347 injection Methods 0.000 description 23
- 239000007924 injection Substances 0.000 description 23
- 230000001154 acute effect Effects 0.000 description 20
- 102100032859 Protein AMBP Human genes 0.000 description 14
- 208000019206 urinary tract infection Diseases 0.000 description 14
- 210000003630 histaminocyte Anatomy 0.000 description 12
- 238000002203 pretreatment Methods 0.000 description 12
- 230000000241 respiratory effect Effects 0.000 description 12
- 208000030961 allergic reaction Diseases 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 8
- 230000036427 bronchial hyperreactivity Effects 0.000 description 8
- 206010006482 Bronchospasm Diseases 0.000 description 7
- 210000000621 bronchi Anatomy 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 208000009079 Bronchial Spasm Diseases 0.000 description 6
- 208000014181 Bronchial disease Diseases 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 229960001334 corticosteroids Drugs 0.000 description 6
- 230000004941 influx Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 210000003979 eosinophil Anatomy 0.000 description 5
- 230000035874 hyperreactivity Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 4
- 229960004484 carbachol Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000014508 negative regulation of coagulation Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000009961 allergic asthma Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 208000023819 chronic asthma Diseases 0.000 description 3
- 229960000265 cromoglicic acid Drugs 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000002327 eosinophilic effect Effects 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 102100021496 Insulin-degrading enzyme Human genes 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003557 Asthma exercise induced Diseases 0.000 description 1
- 206010005042 Bladder fibrosis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000011107 Diacylglycerol Kinase Human genes 0.000 description 1
- 108010062677 Diacylglycerol Kinase Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000057955 Eosinophil Cationic Human genes 0.000 description 1
- 102000056703 Eosinophil Major Basic Human genes 0.000 description 1
- 108700016651 Eosinophil Major Basic Proteins 0.000 description 1
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710097214 Protein N-terminal asparagine amidohydrolase Proteins 0.000 description 1
- 102100034233 Protein N-terminal asparagine amidohydrolase Human genes 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000008369 airway response Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 230000001813 broncholytic effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 108700025647 major vault Proteins 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/904,565 US5980865A (en) | 1995-08-18 | 1997-08-04 | Method for treating late phase allergic reactions and inflammatory diseases |
| PCT/US1998/016111 WO1999006025A1 (fr) | 1997-08-04 | 1998-08-04 | Procede et compositions permettant de traiter des reactions allergiques et des troubles inflammatoires tardifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA75022C2 true UA75022C2 (en) | 2006-03-15 |
Family
ID=25419368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2000020607A UA75022C2 (en) | 1997-08-04 | 1998-04-08 | Method for treating late phase allergic reactions or inflammatory diseases and pharmaceutical composition |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US5980865A (fr) |
| EP (1) | EP1003479B1 (fr) |
| JP (1) | JP2001511439A (fr) |
| KR (1) | KR100551773B1 (fr) |
| CN (1) | CN1092049C (fr) |
| AR (1) | AR005221A1 (fr) |
| AT (1) | ATE323500T1 (fr) |
| AU (1) | AU8684698A (fr) |
| BR (1) | BR9811823A (fr) |
| CA (1) | CA2298445C (fr) |
| DE (1) | DE69834256T2 (fr) |
| DK (1) | DK1003479T3 (fr) |
| ES (1) | ES2260843T3 (fr) |
| HK (1) | HK1030370A1 (fr) |
| HU (1) | HUP0003013A3 (fr) |
| IL (1) | IL134230A0 (fr) |
| NO (1) | NO20000558L (fr) |
| NZ (1) | NZ502498A (fr) |
| PL (1) | PL191796B1 (fr) |
| PT (1) | PT1003479E (fr) |
| RU (1) | RU2209624C2 (fr) |
| SK (1) | SK1172000A3 (fr) |
| TW (1) | TW585771B (fr) |
| UA (1) | UA75022C2 (fr) |
| WO (1) | WO1999006025A1 (fr) |
| ZA (1) | ZA986890B (fr) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050220909A1 (en) * | 2004-03-30 | 2005-10-06 | Theoharides Theoharis C | Composition for protection against superficial vasodilator flush syndrome |
| US20080153761A1 (en) * | 1998-04-08 | 2008-06-26 | Theoharides Theoharis C | Compositions for protection against superficial vasodilator flush syndrome, and methods of use |
| US6984667B2 (en) * | 1998-04-08 | 2006-01-10 | Theta Biomedical Consulting And Development Co. | Synergistic proteoglycan compositions for inflammatory conditions |
| US7906153B2 (en) * | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
| US6689748B1 (en) * | 1998-04-08 | 2004-02-10 | Theoharis C. Theoharides | Method of treating mast cell activation-induced diseases with a proteoglycan |
| US7799766B2 (en) * | 1998-04-08 | 2010-09-21 | Theta Biomedical Consulting & Development Co., Inc. | Composition for treating hormonally-dependent cancers |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| GB9917092D0 (en) | 1999-07-22 | 1999-09-22 | Ml Lab Plc | Treatment of angiogenesis-dependent conditions |
| US20040230559A1 (en) * | 1999-08-09 | 2004-11-18 | Mark Newman | Information processing device and information processing method |
| US20040224922A1 (en) * | 1999-08-26 | 2004-11-11 | Malcolm King | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
| GB0003048D0 (en) * | 2000-02-11 | 2000-03-29 | Dealler Stephen F | The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism |
| SE0001631D0 (sv) * | 2000-05-04 | 2000-05-04 | Sahltech Ab | New use |
| CA2410577A1 (fr) * | 2000-05-23 | 2001-12-13 | The Trustees Of Columbia University In The City Of New York | Procede de traitement des troubles respiratoires associes a une lesion de la fibre elastique pulmonaire |
| CA2516318C (fr) | 2002-02-18 | 2011-07-19 | University Of Southampton | Utilisation de glycosaminoglycanes comme l'heparine pour traiter des maladies respiratoires comme la mpoc |
| ATE385193T1 (de) | 2002-03-20 | 2008-02-15 | Mannkind Corp | Inhalationsgerät |
| WO2003090763A1 (fr) * | 2002-04-24 | 2003-11-06 | Medicarb Ab | Composition et ensemble de traitement de maladies intestinales inflammatoires |
| US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
| EP1607095A1 (fr) * | 2003-03-25 | 2005-12-21 | Sekisui Chemical Co., Ltd. | Composition antipruritique destinee a l'usage externe cutane |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| US7923043B2 (en) * | 2004-03-30 | 2011-04-12 | Theta Biomedical Consulting & Development Co., Inc. | Method for protecting humans against superficial vasodilator flush syndrome |
| CA2575692C (fr) | 2004-08-20 | 2014-10-14 | Mannkind Corporation | Catalyse de la synthese de dicetopiperazine |
| BR122019022692B1 (pt) | 2004-08-23 | 2023-01-10 | Mannkind Corporation | Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo |
| JP2008512403A (ja) | 2004-09-10 | 2008-04-24 | ファルマオリジン・アンパルトセルスカブ | 局所的な気管、気管支、または肺胞の出血または喀血の治療方法 |
| TW200621794A (en) * | 2004-10-06 | 2006-07-01 | Akzo Nobel Nv | Pulmonary administration of an antithrombotic compound |
| US8569367B2 (en) | 2004-11-16 | 2013-10-29 | Allergan, Inc. | Ophthalmic compositions and methods for treating eyes |
| DK1937219T3 (en) | 2005-09-14 | 2016-02-15 | Mannkind Corp | A method for drug formulation based on increasing the affinity of the crystalline surfaces of the microparticle of active principles |
| US8057840B2 (en) * | 2006-01-25 | 2011-11-15 | Tate & Lyle Ingredients Americas Llc | Food products comprising a slowly digestible or digestion resistant carbohydrate composition |
| IN2015DN00888A (fr) | 2006-02-22 | 2015-07-10 | Mannkind Corp | |
| CN101095693B (zh) * | 2006-06-29 | 2010-10-13 | 重庆华邦制药股份有限公司 | 治疗皮炎的复方药物 |
| CN101686996B (zh) * | 2007-05-31 | 2012-12-05 | 格莱肯生物科学公司 | 硫酸木聚糖在制备用于治疗或预防呼吸疾病的药物的新用途 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| KR101933816B1 (ko) | 2008-06-13 | 2019-03-29 | 맨카인드 코포레이션 | 건조 분말 흡입기 및 약물 투여 시스템 |
| EP2609954B1 (fr) | 2008-06-20 | 2021-12-29 | MannKind Corporation | Appareil interactif pour l'établissement en temps réel d'un profil des efforts d'inhalation |
| TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| MY157166A (en) | 2009-06-12 | 2016-05-13 | Mankind Corp | Diketopiperazine microparticles with defined specific surface areas |
| US9176146B2 (en) * | 2009-08-03 | 2015-11-03 | Theta Biomedical Consulting & Development Co., Inc. | Methods of treating autism spectrum disorders and compositions for same |
| US9050275B2 (en) * | 2009-08-03 | 2015-06-09 | Theta Biomedical Consulting & Development Co., Inc. | Methods of screening for and treating autism spectrum disorders and compositions for same |
| JP5784622B2 (ja) | 2009-11-03 | 2015-09-24 | マンカインド コーポレ−ション | 吸入活動をシミュレートするための装置及び方法 |
| RU2576033C2 (ru) * | 2009-12-03 | 2016-02-27 | Опко Хелс, Инк. | Составы на основе гиперсулфатированных дисахаридов |
| US20110212181A1 (en) * | 2010-02-26 | 2011-09-01 | The University Of Hong Kong | Compositions and methods for treating chronic respiratory inflammation |
| RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| US20130203695A1 (en) * | 2010-10-29 | 2013-08-08 | Opko Health, Inc. | Hypersulfated disaccharides to treat elastase related disorders |
| JP6133270B2 (ja) | 2011-04-01 | 2017-05-24 | マンカインド コーポレイション | 薬剤カートリッジのためのブリスター包装 |
| EP2706990A1 (fr) * | 2011-05-12 | 2014-03-19 | Aventis Pharma S.A. | Sémuloparine pour la prévention de thromboembolisme veineux chez des patients cancéreux recevant une chimiothérapie |
| WO2012174472A1 (fr) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | Microparticules de dicétopipérazine de capacité élevée |
| US8957048B2 (en) | 2011-10-06 | 2015-02-17 | Allergan, Inc. | Compositions for the treatment of dry eye |
| CA2852536A1 (fr) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Procedes et compositions pour traiter la douleur |
| US9907826B2 (en) | 2011-12-07 | 2018-03-06 | Allergan, Inc. | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
| ES2896336T3 (es) | 2011-12-07 | 2022-02-24 | Allergan Inc | Suministro eficiente de lípidos a película lagrimal humana usando un sistema de emulsión sensible a sales |
| ES2624294T3 (es) | 2012-07-12 | 2017-07-13 | Mannkind Corporation | Sistemas de suministro de fármacos en polvo seco |
| EP2911690A1 (fr) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Compositions et procédés de vaccin antigrippal inhalable |
| EP2970149B1 (fr) | 2013-03-15 | 2019-08-21 | MannKind Corporation | Compositions de dicétopipérazine microcristallines et procédés |
| BR112016000937A8 (pt) | 2013-07-18 | 2021-06-22 | Mannkind Corp | formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco |
| CA2920488C (fr) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Appareil d'insufflation et procedes |
| WO2015148905A1 (fr) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Utilisation d'insuline à action ultrarapide |
| EP3191091B1 (fr) | 2014-09-12 | 2020-08-26 | Children's Medical Center Corporation | Formulations d'émulsions alimentaires et leurs méthodes d'utilisation |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| KR102487299B1 (ko) | 2014-11-25 | 2023-01-10 | 알러간, 인코포레이티드 | 안정화된 오메가-3 안과용 조성물 |
| WO2018035050A1 (fr) | 2016-08-16 | 2018-02-22 | Opko Pharmaceuticals, Llc | Disaccharides heptasulfatés purs à biodisponibilité orale améliorée |
| KR20190093214A (ko) | 2016-12-13 | 2019-08-08 | 베타 테라퓨틱스 피티와이 리미티드 | 헤파라나제 억제제 및 그의 용도 |
| US11787783B2 (en) | 2016-12-13 | 2023-10-17 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
| CN114053251A (zh) * | 2020-07-29 | 2022-02-18 | 苏州融析生物科技有限公司 | 硫酸化多糖吸入制剂及其在防治新冠病毒相关疾病中的应用 |
| US20220211746A1 (en) * | 2021-01-07 | 2022-07-07 | Bionovax Corp. | Special heparinoid composition, with repair, prophylactic and anti-inflammatory effects, applied to the lungs |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3405120A (en) * | 1966-01-27 | 1968-10-08 | Green Cross Corp | Low molecular chondroitin sulfate and method for manufacturing the same |
| IT1195497B (it) | 1983-03-08 | 1988-10-19 | Opocrin Spa | Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina |
| US4847338A (en) * | 1985-03-28 | 1989-07-11 | University Of Iowa Research Foundation | Low molecular weight heparin fragments as inhibitors of complement activation |
| FR2584728B1 (fr) * | 1985-07-12 | 1987-11-20 | Choay Sa | Procede de sulfatation de glycosaminoglycanes et de leurs fragments |
| FR2584606A1 (fr) * | 1985-07-12 | 1987-01-16 | Dropic | Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif |
| IT1230582B (it) * | 1988-10-21 | 1991-10-28 | Opocrin S P A Lab Farmabiologi | Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica |
| US5380716A (en) | 1988-12-15 | 1995-01-10 | Glycomed, Inc. | Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation |
| US5032679A (en) | 1988-12-15 | 1991-07-16 | Glycomed, Inc. | Heparin fragments as inhibitors of smooth muscle cell proliferation |
| AU668865B2 (en) * | 1991-05-02 | 1996-05-23 | Irun R. Cohen | Compositions for the prevention and/or treatment of pathological processes |
| AU6204594A (en) * | 1993-02-22 | 1994-09-14 | Ulrich-Christoph Von Arnim | Use of heparins for the treatment of inflammatory or immunological diseases |
| FR2704861B1 (fr) * | 1993-05-07 | 1995-07-28 | Sanofi Elf | Fractions d'héparine purifiées, procédé d'obtention et compositions pharmaceutiques les contenant. |
| US5527785A (en) * | 1993-05-14 | 1996-06-18 | The Regents Of The University Of California | Selectin receptor modulating compositions |
| SE9303612D0 (sv) * | 1993-11-02 | 1993-11-02 | Kabi Pharmacia Ab | New use |
| US5690910A (en) * | 1995-08-18 | 1997-11-25 | Baker Norton Pharmaceuticals, Inc. | Method for treating asthma |
-
1997
- 1997-08-04 US US08/904,565 patent/US5980865A/en not_active Expired - Lifetime
-
1998
- 1998-04-08 UA UA2000020607A patent/UA75022C2/uk unknown
- 1998-07-31 ZA ZA986890A patent/ZA986890B/xx unknown
- 1998-08-03 AR ARP980103829A patent/AR005221A1/es not_active Application Discontinuation
- 1998-08-04 KR KR1020007001123A patent/KR100551773B1/ko not_active IP Right Cessation
- 1998-08-04 JP JP2000504840A patent/JP2001511439A/ja not_active Withdrawn
- 1998-08-04 SK SK117-2000A patent/SK1172000A3/sk unknown
- 1998-08-04 DK DK98938290T patent/DK1003479T3/da active
- 1998-08-04 ES ES98938290T patent/ES2260843T3/es not_active Expired - Lifetime
- 1998-08-04 NZ NZ502498A patent/NZ502498A/en not_active IP Right Cessation
- 1998-08-04 IL IL13423098A patent/IL134230A0/xx unknown
- 1998-08-04 BR BR9811823-4A patent/BR9811823A/pt not_active Application Discontinuation
- 1998-08-04 HU HU0003013A patent/HUP0003013A3/hu unknown
- 1998-08-04 CA CA002298445A patent/CA2298445C/fr not_active Expired - Fee Related
- 1998-08-04 AU AU86846/98A patent/AU8684698A/en not_active Abandoned
- 1998-08-04 AT AT98938290T patent/ATE323500T1/de active
- 1998-08-04 WO PCT/US1998/016111 patent/WO1999006025A1/fr not_active Application Discontinuation
- 1998-08-04 DE DE69834256T patent/DE69834256T2/de not_active Expired - Lifetime
- 1998-08-04 PL PL338551A patent/PL191796B1/pl unknown
- 1998-08-04 CN CN98808919A patent/CN1092049C/zh not_active Expired - Fee Related
- 1998-08-04 PT PT98938290T patent/PT1003479E/pt unknown
- 1998-08-04 RU RU2000105383/14A patent/RU2209624C2/ru not_active IP Right Cessation
- 1998-08-04 EP EP98938290A patent/EP1003479B1/fr not_active Expired - Lifetime
- 1998-08-05 TW TW087112755A patent/TW585771B/zh not_active IP Right Cessation
-
1999
- 1999-05-04 US US09/304,814 patent/US6193957B1/en not_active Expired - Lifetime
-
2000
- 2000-02-03 NO NO20000558A patent/NO20000558L/no not_active Application Discontinuation
-
2001
- 2001-02-23 HK HK01101310A patent/HK1030370A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA75022C2 (en) | Method for treating late phase allergic reactions or inflammatory diseases and pharmaceutical composition | |
| EP0844869B1 (fr) | Ulmwh (heparines a poids moleculaire ultra-bas) pour traiter l'asthme | |
| JP4585121B2 (ja) | 薬剤療法に対する寛容を予防するための方法と組成物 | |
| WO1993019734A1 (fr) | Procede et composition de traitement de l'asthme provoque par un antigene et par l'effort | |
| ES2258145T3 (es) | Disacaridos hipersulfatados y procedimientos para la utilizacion de los mismos en el tratamiento de las inflamaciones. | |
| AU775161B2 (en) | Method and compositions for treating late phase allergic reactions and inflammatory diseases | |
| RU2179445C2 (ru) | Способ и композиция для лечения астмы | |
| MXPA00000992A (en) | Method and compositions for treating late phase allergic reactions and inflammatory diseases | |
| MXPA98001165A (en) | Method and composition for the treatment of the | |
| CZ2000426A3 (cs) | Farmaceutický přípravek k léčení pozdní fáze alergické reakce a zánětlivé nemoci | |
| EP1462148A2 (fr) | Procédés et compositions pour prévenir la tolérance à des bronchodilateurs |